282 related articles for article (PubMed ID: 11684722)
1. p21(waf) correlates with DNA replication but not with prognosis in invasive breast cancer.
Göhring UJ; Bersch A; Becker M; Neuhaus W; Schöndorf T
J Clin Pathol; 2001 Nov; 54(11):866-70. PubMed ID: 11684722
[TBL] [Abstract][Full Text] [Related]
2. Expression of the cell cycle regulatory proteins p34cdc2, p21waf1, and p53 in node negative invasive ductal breast carcinoma.
Kourea HP; Koutras AK; Scopa CD; Marangos MN; Tzoracoeleftherakis E; Koukouras D; Kalofonos HP
Mol Pathol; 2003 Dec; 56(6):328-35. PubMed ID: 14645695
[TBL] [Abstract][Full Text] [Related]
3. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
Göhring UJ; Scharl A; Ahr A
Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
[TBL] [Abstract][Full Text] [Related]
4. Quantitative p21(waf-1)/p53 immunohistochemical analysis defines groups of primary invasive breast carcinomas with different prognostic indicators.
Ceccarelli C; Santini D; Chieco P; Lanciotti C; Taffurelli M; Paladini G; Marrano D
Int J Cancer; 2001 Mar; 95(2):128-34. PubMed ID: 11241324
[TBL] [Abstract][Full Text] [Related]
5. p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival.
Barbareschi M; Caffo O; Doglioni C; Fina P; Marchetti A; Buttitta F; Leek R; Morelli L; Leonardi E; Bevilacqua G; Dalla Palma P; Harris AL
Br J Cancer; 1996 Jul; 74(2):208-15. PubMed ID: 8688323
[TBL] [Abstract][Full Text] [Related]
6. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1) in urothelial carcinoma: correlation with other cell-cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features.
Ioachim E; Michael M; Stavropoulos NE; Kitsiou E; Hastazeris K; Salmas M; Stefanaki S; Agnantis NJ
Urol Int; 2004; 73(1):65-73. PubMed ID: 15263796
[TBL] [Abstract][Full Text] [Related]
7. Expression of cyclins A and D and p21(waf1/cip1) proteins in renal cell cancer and their relation to clinicopathological variables and patient survival.
Aaltomaa S; Lipponen P; Ala-Opas M; Eskelinen M; Syrjänen K; Kosma VM
Br J Cancer; 1999 Aug; 80(12):2001-7. PubMed ID: 10471053
[TBL] [Abstract][Full Text] [Related]
8. p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis.
Pellikainen MJ; Pekola TT; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
J Clin Pathol; 2003 Mar; 56(3):214-20. PubMed ID: 12610102
[TBL] [Abstract][Full Text] [Related]
9. Mdm2 and the p53 pathway in human pituitary adenomas.
Suliman M; Royds J; Cullen D; Timperley W; Powell T; Battersby R; Jones TH
Clin Endocrinol (Oxf); 2001 Mar; 54(3):317-25. PubMed ID: 11298083
[TBL] [Abstract][Full Text] [Related]
10. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up.
Caffo O; Doglioni C; Veronese S; Bonzanini M; Marchetti A; Buttitta F; Fina P; Leek R; Morelli L; Palma PD; Harris AL; Barbareschi M
Clin Cancer Res; 1996 Sep; 2(9):1591-9. PubMed ID: 9816338
[TBL] [Abstract][Full Text] [Related]
12. Subcellular localisation of cyclin B, Cdc2 and p21(WAF1/CIP1) in breast cancer. association with prognosis.
Winters ZE; Hunt NC; Bradburn MJ; Royds JA; Turley H; Harris AL; Norbury CJ
Eur J Cancer; 2001 Dec; 37(18):2405-12. PubMed ID: 11720835
[TBL] [Abstract][Full Text] [Related]
13. High apoptotic index correlates to p21 and p27 expression indicating a favorable outcome of primary breast cancer patients, but lacking prognostic significance in multivariate analysis.
Schöndorf T; Göhring UJ; Becker M; Hoopmann M; Schmidt T; Rützel S; Rein DT; Ulrich U; Fechteler R; Bersch A; Mallmann P; Valter MM
Pathobiology; 2004; 71(4):217-22. PubMed ID: 15263811
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
15. An immunohistochemical study of p21 and p53 expression in primary node-positive breast carcinoma.
O'Hanlon DM; Kiely M; MacConmara M; Al-Azzawi R; Connolly Y; Jeffers M; Keane FB
Eur J Surg Oncol; 2002 Mar; 28(2):103-7. PubMed ID: 11884043
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer.
Horita K; Yamaguchi A; Hirose K; Ishida M; Noriki S; Imamura Y; Fukuda M
Eur J Histochem; 2001; 45(1):73-84. PubMed ID: 11411868
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
18. Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients.
Gago FE; Tello OM; Diblasi AM; Ciocca DR
J Steroid Biochem Mol Biol; 1998 Dec; 67(5-6):431-7. PubMed ID: 10030692
[TBL] [Abstract][Full Text] [Related]
19. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features.
Ioachim E
Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860
[TBL] [Abstract][Full Text] [Related]
20. p53 as an independent prognostic marker in lymph node-negative breast cancer patients.
Silvestrini R; Benini E; Daidone MG; Veneroni S; Boracchi P; Cappelletti V; Di Fronzo G; Veronesi U
J Natl Cancer Inst; 1993 Jun; 85(12):965-70. PubMed ID: 8496982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
